Video

Dr. Shroff on the Importance of Targeted Therapy in Advanced Biliary Tract Cancer

Rachna T. Shroff, MD, discusses the importance of targeted therapy in advanced biliary tract cancer.

Rachna T. Shroff, MD, associate dean, Clinical and Translational Research, associate professor, Medicine in the Clinical Scholar Track, chief, Section of GI Medical Oncology, director, University of Arizona (UA) Cancer Center, director, UA Cancer Center Clinical Trials Office, UA Health Sciences, discusses the importance of targeted therapy in advanced biliary tract cancer.

It is an exciting time for drug development in biliary tract cancers, as 3 novel targeted therapies have been FDA approved for cholangiocarcinoma within the past 2 years, Shroff explains. With additional therapies in the pipeline, the importance of targeted therapy in this patient population remains arelevant research effort, Shroff adds.

The process of biomarker testing in biliary tract cancers identified actionable targets, which underscores the importance of molecular testing with next-generation sequencing for all patients with newly diagnosed disease, Shroff explains. Moreover, up to 40% of patients could harbor an actionable target that could make them eligible for an approved targeted therapy or a clinical trial, Shroff concludes.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.